Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Put your claims and concerns in an email and shoot it to the bankruptcy trustee. All of us who can substantiate egregious behavior should also be engaged with the trustee.
Irrelevant.
I would like to attend the hearing, but, unlike an annual meeting, hearings can be postponed as was the case with Medizone. I did send a letter, via email, to Mr. Schwartzer offering a little history of the last decade of the company and how shareholders were deprived of representation between 2009 and 2016. If the recent press releases were true, our new management was engaged with the FDA, was working on a global social media awareness program with Innovasource, and was in the middle of a fund raising campaign. Would you or I, as a prior officer of the company holding several million shares, cut-off the only momentum the company had seen in its lifetime? Both of these bankruptcies should be thrown out, and the old and new management should be at the negotiating table working out a payment plan while prospects for the business forge ahead.
Where?
Penny Land can be a strange place. Most companies never develop a product or service, but the continuous hype of that potential product or service is what keeps CEOs getting paid. The thought process is very short sighted: a paycheck every month at the expense of shareholders versus a true product/service development program that would make BODs and shareholders very wealthy upon introduction. It must have been too much work.
Oh......The proposal will be "properly presented" at the meeting.......in person by me. It's really important that shareholders become proactive and vote YES to rescind this preferred issue. Elis.....can you share a few of your thoughts on this rescission?
The preferred issue hurts the shareholders for the reasons I mentioned in my previous post. Why would we want to thwart a potential suitor? Management won't voluntarily rescind the issue, so we, as shareholders, are going to vote it out of existence.
Okay....It's time to rally the troops. I have re-submitted my entry from 2016 to rescind the entire preferred stock offering that continues to sit on the shelf. That offering is NOT in the best interest of the common stock shareholder. Look at management's own wording in the latest 10-K and S-1. It is dilutive. It can hamper voting rights. It can thwart a potential suitor. Need I say more? You can read the verbatim quotes when the prospectus arrives. Watch out for double negatives in the wording. We are voting TO RESCIND the preferred stock offering.
There is no reason, in shareholders' best interests, for the preferred issue to remain in the shadows. It needs to be gone. Two years ago I made that formal proposal before the shareholder meeting, and it was defeated.
I am going to encourage any and all minority shareholders to attend this meeting.
Medizone, unfortunately right now, is relegated to bargaining from a position of weakness instead of from a position of strength. Five years of zero social media awareness, zero follow-up testing, and an unfocused BOD has caused this situation. It's not rocket science. It's simply not attending to the business at hand from all possible angles. The most significant public decontamination device in the history of man has been created, and no one seems to know what to do with it (including the FDA). Let's hope this crew can finally figure it out.
Was this article relevant to GTHP this week?
So what's our EPA that Medizone spent years navigating....chopped liver? No one cares about the EPA approval?
I will credit Esposito for amassing the most experienced group this fledgling company has ever had. Most experienced health care people are not going to drop down to take on a fledgling operation like Medizone. When one has a red flag on his/her resume' and needs to prove something to "the street", however, turning around a tiny, flailing organization can be just what the proverbial doctor ordered to ensure future employment. We have waited five years to capitalize on the Belleville success. Maybe Dodd reads our posts and realizes how much time has been wasted and who wasted it. The company has serious cash flow problems because the faith needed to secure PPLs disappeared. I could be a fresh buyer of PPLs given the commitment of Dodd's latest shareholder letter. Still, it has taken them several months to report to us about what to do. One would have thought Esposito and Caponi could have told them what's what six months ago.
I don't think any of us, at the time, realized that Esposito would be giving so little effort to the promotion of AS from 2013-17. He is working his way out from under Armune, but that sale has been no feather in his cap. A few members of his current crew have proven that they are very good at spending shareholders' money, but the jury is still out with their ability to produce revenues. Innovasource has shown us nothing in two years. Rank amateur distributors have shown us nothing in three years. Shareholders again need to mobilize and create a concerted effort to hold management feet to the fire this time. We need to watch this situation very closely. The 10k, Innovasource announcement, and yanking of the S-1 came in rapid succession and need to be explained immediately.
No announcement of financing has taken place. The stock is under a penny. No news from Turkey. Where is GC, and is this company still in business? Has anyone called the home office recently? I have. It's a series of recordings no matter whose number you punch.
According to Zoominfo, Zoutman, as of 10-7-17, is the Chief of Staff for Human Resources for the Belleville General Hospital Foundation.
Esposito is aware that the Gates/Rotary Foundations could do Medizone a world of good. I was not implying impropriety, Green, I was implying that entities have been paid for services not rendered......yet. I guess the jury is still out on our "distributors"
The newest employee/Board member, fortunately, has credentials that trump his other Board peers. I think we're all in agreement these days that three things need to happen for Medizone. 1. It embarks on a testing program that produces results similar to Belleville. 2. It embarks on a global awareness program to advertise the existence of Asepticsure and its test successes. 3. It FINALLY obtains the last approval needed to begin global marketing.
Medizone management, over the last few years, has given away part of the farm to entities that have produced nothing in return. This practice has to stop, and qualified, competent people have to be engaged outside the firm to help move the company forward.
The reality continues that the FDA cannot keep a domestic company from selling its products overseas when they are approved there. Another example is tiny Guided Therapuetics out of Atlanta. The FDA has turned it down three times, but the company is doing business in several countries around the globe and is working on many more. It's a device as well. LuViva is a light activated system that can give immediate readings on cervical cancer without pap smears and other lab work. The developing world is starting to pick up on it. I don't imagine domestic laboratories are too keen about it being introduced here at some point.
Aurinia re-traced over 50% of its original gain while the general markets were rising. So when the general markets got clobbered, Aurinia fell just a little over 10%. Can it go to $2? Sure. It's a stock. Current prospects, however, should put a floor underneath this stock at close to current levels. What could drop it farther? Another general market devaluation could do it. The biggest culprits, however, would be untimely reporting delays and/or a reduction in efficacy numbers from Phase III test results. We know to not expect any answers for several more months. So the waiting game continues, and we have to realize that, at times, the attitude of the general market will have an affect on Aurinia....psychological if nothing else.
Hi BZ and Welcome. I think our message board members would be very interested in opinions rendered by the doctors with whom you have become friends. Can you share the web site info, peer review material, and recent developments with them?
Hi Joe. The problem seems to be that no real-life testing was done after Belleville. That test took place almost five years ago. What has happened in the mean time that goes beyond the petri dish?
Petri dish testing is one thing. Real life testing of the actual room, so that both efficacy and safety can be measured, is a totally different ballgame.
I rest my case of the last five years: testing, testing, and more testing. I hold everyone on the two boards responsible for this oversight that is causing an additional two year delay to marketing approval in the U.S.......and I mean everyone.
Why shouldn't he follow suit and surrender? What has he done to earn them?
It was as recent as November 2016.
How would old management know what would work and not work? No social media awareness marketing programs were done, and the office rarely had someone occupying it.
Thanks for all the clarifications. I have been following biotech for the better part of three decades, and it's just second nature for me to scratch my head and wonder what could go wrong with a specific situation.
My thoughts about any Phase 3 trial, in general, revolve around efficacy at a tougher level than Phase 2. A lot of product, over the years, met side-effect end-points but didn't meet efficacy endpoints and were thereby terminated. Realizing that Phase 2 is side-effect oriented, even more-so than efficacy oriented, I need help seeing the bigger picture through a Phase 3 test where the patients are easier (healthier) to treat than in the Phase 2 test. Wouldn't the results of Phase 3 be more convincing if the degree of difficulty obtaining the desired results was the same or higher than the Phase 2 test? I get it that Phase 2 efficacy endpoints were met with flying colors. Why would the company backtrack on the degree of difficulty for Phase 3 when a more difficult Phase 2 was successful? Just remembering a little general FDA history and thinking out loud..................Guidance is appreciated.
Interesting post, Semper. What if a new term, "docking for decontamination" was adopted so ships could undergo an annual "check-up"? Cruise ship demand could increase dramatically. The kitchens remain the immediate problem, and down time could be modified a bit to accommodate the needed eradication.
The Turkish deal is good news, and a China deal someday should dwarf it. The FDA has been wanting updated material from Guided for over two years. It looks like the funding finally is there to make it happen. All we can do now is hope Guided gives the FDA what it needs this time. Three TDs ( turns-down) is never encouraging.
I read into Dodd's commentary the need for global awareness through social media marketing. Web sites don't cut the mustard if the product isn't known. Intensified awareness can create testing situations. Successful test results can put pressure on governments. Can we imagine some day where a family, who has lost a member to an HAI, sues the hospital AND the government for failing to allow a proven decontamination process to perform?
Execution, however, BenK, was and is the primary culprit of all the management teams, including the current one.
It used to trade under $5 every day for a long time when leverage didn't matter. Now leverage can have its own affect.
Let's all try to remember that shareholders have different short term needs and long term needs. Everyone is unique. Situations change with people. It's a fact of life. A choice to sell a certain stock may have a dozen different material/psychological factors affecting the decision. We can't control other shareholders. What we can do is stick to our convictions and realize that this journey is going to take a couple of years. Patience has a history of being rewarded.
Hence why I believe WIV should be on the Board of Directors...at the very least.
Hi Wstinsider. Can you give us any updates on South America? Do you think AS will run into similar regulatory requirements in the Nordic region as it has in South America?
Aurinia is not a short term play. Several other areas of this market, however, are. Where does one make money today in an up market? It's not with AUPH.
I will admit to caring about this company and its technological capabilities for the better part of thirty years. I had nothing to do, however, with effecting a management change. What I did, twenty months ago, was become proactive with minority shareholders. Our Board moderators are to be thanked for allowing me to bend the rules just a little bit to post "Go To Meeting" numbers and codes so that shareholders could have an audio forum in which to convene. The result, between the calls and the subsequent emails, was a pledge of shares in excess of the minimum needed to demand the convening of a special shareholder meeting had we not been able to meet in Salt Lake City last December. The new CEO, at that time, was informed of our meetings and their results. I personally believe WhatIsValue should be on the Medizone Board of Directors. His detailed analysis of many of our issues has been "spot-on".